Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. OFEV
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

OFEV

Medicine - Posted on Feb 10 2023
Active substance (DCI)
  • nintédanib
history (4)
  • 1/18/23

    OFEV (nintedanib) - Pulmonary fibrosis

    Reassessment. Key points Favourable opinion for maintenance of reimbursement in the idiopathic pulmonary fibrosis indication...
    CAV :
    54321
    icône flèche
  • 12/16/20

    OFEV - PID-ScS chez l’adulte (nintedanib)

    Key points Favourable opinion for reimbursement in the treatment of systemic sclerosis associated interstitial lung disease ...
    CAV :
    54321
    icône flèche
  • 12/16/20

    OFEV - PID (nintedanib)

    Key points Favourable opinion for reimbursement in the treatment of other chronic fibrosing interstitial lung diseases (ILDs...
    CAV :
    54321
    icône flèche
  • 5/20/15

    OFEV (nintedanib), inhibitor of tyrosine kinases

    Minor improvement in the treatment of idiopathic pulmonary fibrosis in patients with a predicted FVC ≥ 50% and a DLco ≥ 30%....
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01EX09
Manufacturer
BOEHRINGER INGELHEIM FRANCE
Presentation

OFEV 100 mg, capsule molle (code CIS : 62388307)
60 plaquette(s) thermoformée(s) aluminium de 1 comprimé(s) (CIP : 34009 300 060 2 3)

OFEV 150 mg, capsule molle (code CIS : 62960765)
60 plaquette(s) thermoformée(s) aluminium de 1 comprimé(s) (CIP : 34009 300 060 4 7)

All our publications
    Congenital, genetic and rare diseases Drug therapy Pulmonary and pleural diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
p8GBp1xsp7hADsxs